By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 128.48 |
Change Today | $ -2.19 |
% Change | -1.68 % |
52 Week High | $133.73 |
52 Week Low | $127.97 |
Volume | 559,140 |
Shares Issued | 145.80m |
Market Cap | $18,732m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 21 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
14:50 | 100 @ $128.48 |
14:50 | 100 @ $128.49 |
14:49 | 100 @ $128.53 |
14:49 | 100 @ $128.53 |
14:49 | 100 @ $128.53 |
You are here: research